Annexon/$ANNX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Annexon
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
- Ticker
- $ANNX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 97
- Headquarters
- Brisbane, United States
- Website
- www.annexonbio.com
Annexon Metrics
BasicAdvanced
$799M
-
-$1.03
1.44
-
Price and volume
Market cap
$799M
Beta
1.44
52-week high
$7.18
52-week low
$2.54
Average daily volume
3.6M
Financial strength
Current ratio
5.786
Quick ratio
5.666
Long term debt to equity
0.49
Total debt to equity
0.513
Interest coverage (TTM)
-247.03%
Profitability
EBITDA (TTM)
-203.629
Management effectiveness
Return on assets (TTM)
-53.64%
Return on equity (TTM)
-130.80%
Valuation
Price to book
5.58
Price to tangible book (TTM)
5.58
Price to free cash flow (TTM)
-4.282
Free cash flow yield (TTM)
-23.35%
Free cash flow per share (TTM)
-0.979
Growth
Earnings per share change (TTM)
-25.95%
3-year earnings per share growth (CAGR)
-18.47%
What the Analysts think about Annexon
Analyst ratings (Buy, Hold, Sell) for Annexon stock.
Analyst projections of the future price of Annexon stock.
Bulls say / Bears say
In a 242-patient Phase 3 trial, tanruprubart met its primary endpoint in Guillain-Barré syndrome at Week 8, with faster improvement also seen at Week 1. That provides encouraging controlled evidence for the company’s lead programme. (Practical Neurology)
ARCHER II is testing whether vonaprument can preserve vision in geographic atrophy, and its 659-patient trial retains the Month 15 endpoint while adding an independent Month 24 endpoint. The study’s low discontinuation rate and high patient compliance support execution ahead of the coming readouts. (SEC)
Annexon reported $209.2 million in cash and short-term investments at the end of June and expects its resources, including the new credit facility, to fund operations into 2028. This gives it time to pursue key clinical and regulatory milestones without an immediate need to raise equity. (Annexon)
Adding Month 24 as a second primary endpoint leaves open the possibility that the Month 15 result will not settle the question, and could push a definitive trial outcome into 2027. The change was interpreted by investors as a potential sign of uncertainty around the earlier readout. (Annexon, Investing.com)
The Phase 3 GBS study enrolled patients who lacked access to IVIG or plasma exchange, while the initial US and European confirmation consists of just 10 patients in an open-label study. This leaves uncertainty about how well the treatment will perform against standard care in routine practice. (Practical Neurology, Annexon)
Annexon has no approved products and remains loss-making: its second-quarter net loss was $55.3 million, and it used $94.8 million of cash in the first half. The company expects to need further financing, which could mean dilution or additional debt even with its current runway. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Annexon Financial Performance
Revenues and expenses
Annexon Earnings Performance
Company profitability
Upcoming events
No upcoming events
Annexon News
AllArticlesVideos
Funds containing Annexon
Fund name | Fund size | $ANNX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.